- Home
- VIGL vs ARMP Comparison
VIGL vs ARMP Comparison
Compare VIGL & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- ARMP
- Stock Information
- Founded
- VIGL 2020
- ARMP 2016
- Country
- VIGL United States
- ARMP United States
- Employees
- VIGL N/A
- ARMP N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VIGL Health Care
- ARMP Health Care
- Exchange
- VIGL Nasdaq
- ARMP Nasdaq
- Market Cap
- VIGL 89.3M
- ARMP 73.2M
- IPO Year
- VIGL 2022
- ARMP N/A
- Fundamental
- Price
- VIGL $2.10
- ARMP $1.98
- Analyst Decision
- VIGL Strong Buy
- ARMP Strong Buy
- Analyst Count
- VIGL 5
- ARMP 1
- Target Price
- VIGL $21.00
- ARMP $7.00
- AVG Volume (30 Days)
- VIGL 287.9K
- ARMP 11.5K
- Earning Date
- VIGL 05-06-2025
- ARMP 05-06-2025
- Dividend Yield
- VIGL N/A
- ARMP N/A
- EPS Growth
- VIGL N/A
- ARMP N/A
- EPS
- VIGL N/A
- ARMP N/A
- Revenue
- VIGL N/A
- ARMP $5,467,000.00
- Revenue This Year
- VIGL N/A
- ARMP $23.87
- Revenue Next Year
- VIGL N/A
- ARMP N/A
- P/E Ratio
- VIGL N/A
- ARMP N/A
- Revenue Growth
- VIGL N/A
- ARMP 34.92
- 52 Week Low
- VIGL $1.49
- ARMP $1.80
- 52 Week High
- VIGL $6.06
- ARMP $4.25
- Technical
- Relative Strength Index (RSI)
- VIGL 45.86
- ARMP 38.98
- Support Level
- VIGL $2.15
- ARMP $1.94
- Resistance Level
- VIGL $2.55
- ARMP $2.16
- Average True Range (ATR)
- VIGL 0.22
- ARMP 0.15
- MACD
- VIGL -0.04
- ARMP -0.01
- Stochastic Oscillator
- VIGL 20.59
- ARMP 12.24
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.